Shattuck Labs to Participate in Upcoming December Investor Conferences

Shattuck Labs, Inc. (NASDAQ: STTK), a clinical-stage biotechnology firm focused on novel therapeutics targeting tumor necrosis factor superfamily receptors, has announced its participation in several investor conferences scheduled for December 2025. Highlighting its commitment to transparency and engagement with the investment community, CEO Taylor Schreiber, M.D., Ph.D., will present at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 2 and engage in a fireside chat at the Evercore ISI 8th Annual HealthCONx Conference in Coral Gables, Florida, on December 4.

The conferences will offer presentations and one-on-one meetings for investors and analysts to discuss Shattuck’s innovative pipeline, including its lead therapeutic candidate, SL-325. This potential first-in-class antibody is designed to block the Death Receptor 3 (DR3) and is currently being evaluated in a Phase 1 clinical trial. Preclinical studies suggest that SL-325 exhibits high affinity binding and shows superior efficacy compared to traditional TL1A antibodies, supporting the rationale for targeting the DR3 receptor.

Shattuck Labs is headquartered in Austin, Texas, and Durham, North Carolina, and is dedicated to developing treatments for inflammatory and immune-mediated diseases, including inflammatory bowel disease (IBD). The company leverages its expertise in protein engineering to advance cutting-edge TNF receptor therapeutics, with SL-325 representing a significant advancement in the field.

Replays of both presentations will be accessible on the company’s website for up to 30 days following the events, allowing a broader audience to stay informed about Shattuck’s strategic vision and clinical advancements. To engage further, investors can contact Andrew R. Neill, CFO, via the provided email.

Shattuck Labs, Inc. (NASDAQ: STTK) is positioning itself for increased visibility in the biotech market with its participation in several investor conferences this December. The upcoming events, including the Piper Sandler 37th Annual Healthcare Conference and the Evercore ISI 8th Annual HealthCONx Conference, are pivotal for the company as they showcase its innovative therapeutic candidate, SL-325.

Investors should view this as a critical opportunity to gauge Shattuck's strategic direction and advancements in the clinical trial space, particularly for SL-325, its first-in-class Death Receptor 3 (DR3) blocking antibody. The efficacy shown in preclinical studies and the potential to disrupt established treatment paradigms for inflammatory bowel disease (IBD) and other immune-mediated diseases could attract attention from both institutional and retail investors. The focus on a clinically validated pathway, as detailed in the company's communications, indicates a strong data-driven basis for its advancements.

From a financial perspective, engaging with Dr. Taylor Schreiber's presentations could provide insights into SL-325’s progression through Phase 1 clinical trials and any updates on safety profiles or potential market timelines. The upcoming webcasts will also allow for accessible engagement with current and prospective stakeholders, preserving investor interest over the following months as results materialize.

Given the current biotech market's volatility, Shattuck Labs appears to be poised for strategic growth. Investors should remain attentive to the developments discussed at these conferences, and consider evaluating STTK shares for potential long-term appreciation, particularly as positive clinical outcomes could lead to significant stock price movements. Careful monitoring of market reactions to the presentation outcomes will also be crucial in making informed investment decisions.